MELARIS®
OverviewHow to Order
Testing for Hereditary Melanoma

What is MELARIS®?

MELARIS® assesses an individual's risk of developing melanoma, based on the detection of mutations in the p16 gene.

What is the test?

MELARIS® is a genetic test that requires only a small blood sample to determine if a patient has a p16 gene mutation, indicating a predisposition for melanoma. This is the most accurate clinical test available to detect p16 gene mutations.

Why choose MELARIS®?

MELARIS® genetic testing enables the clinician to:
  • Take a proactive management approach with clearly identified at-risk patients
  • Avoid unnecessary interventions in family members who have not inherited a known familial mutation
  • Target increased surveillance and other interventions to individuals with a p16 mutation – maximising patient care while increasing clinical efficiency
  • Counsel patients and family members on the underlying cause of cancer, in the case of a positive result. Significantly improve patient outcomes.
How can I order MELARIS® from Lab21?

MELARIS® testing requires a blood sample, and it can only be requested by a medical doctor. To request MELARIS® testing service, simply contact the dedicated  Lab21 Customer Services Team.

The turnaround time is 21 working days from the receipt of the sample at Lab21. A rapid option with 12-day turnaround time is also available.

References
  1. Beaudet AL, Tsui LC. A suggested nomenclature for designating mutations. Hum Mut 1993; 2:245-248
  2. Burden et al. Genetic and environmental influences in the development of multiple primary melanoma. Arch Dermatol, 1999; 135: 261-265.
  3. Greene. The genetics of hereditary melanoma and nevi. 1998 update. Cancer, 1999; 86: 2464-2477.
  4. Hayward. New developments in melanoma genetics. Curr Oncol Rep, 2000; 2: 300-306.
Myriad and MELARIS are either trademarks or registered trademarks of Myriad Genetics, Inc in the United States and other jurisdictions.

Other Services


Colorectal Cancer

Lung Cancer
Breast and Ovarian Cancer
Cancer of Unknown Primary
Skin Cancer
More
);